Fennec reports Q2 EPS (11c), consensus (3c)

Reports Q2 revenue $9.7M, consensus $9.56M. “We are pleased to have delivered three consecutive quarters of strong performance, with Q2 revenue up 33% over the same quarter in 2024. This acceleration reflects significant progress in both large community practices and academic centers – driven by a completely overhauled go-to-market approach, increased awareness of the importance of preventing cisplatin-induced ototoxicity and expanded patient support program offerings,” said CEO Jeff Hackman. “The results demonstrate the scalability of our model and the strong demand for PEDMARK across key segments of the market. With the U.S. momentum for PEDMARK building, coupled with Norgine’s ex-U.S. PEDMARQSI(R) launches and results from the investigator-initiated clinical trial STS-J01 in Japan expected in the coming months, we believe the global opportunity for both patients and Fennec (FENC) shareholders is significant.”